This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Reid, J. M. Search for Related Content PubMed PubMed Citation Articles by Reid, J. M. Related Collections Clinical Intervention Clinical Intervention:Molecular Targeted Drugs Clinical Intervention: Early-Phase (I/II) Clinical or Translational Trials

Comparative Bioavailability of Sulindac in Capsule and Tablet Formulations

¹ Mayo Clinic College of Medicine, Rochester, Minnesota and ² Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: Paul J. Limburg, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Phone: 507-266-4338; Fax: 507-266-0350. E-mail: limburg.paul{at}mayo.edu

The cyclooxygenase (COX)-2 enzyme appears to be an important target for cancer chemoprevention. Given the recent emergence of potentially serious cardiovascular toxicity associated with selective COX-2 inhibitors, nonsteroidal antiinflammatory drugs (NSAIDs), which inhibit both COX-1 and COX-2, have received renewed attention as candidate chemoprevention agents. Sulindac has shown consistent chemopreventive potential in preclinical studies as well as in a limited number of clinical trials reported to date. For the current pharmacokinetic study, sulindac capsules were prepared to facilitate ample agent supplies for future intervention studies. Encapsulation of the parent compound (sulindac sulfoxide) can be readily accomplished, but the effects of alternate formulations on bioavailability have not been rigorously examined. In the present single-dose, two-period crossover trial, we conducted pharmacokinetic analyses of sulindac in capsule (test) versus tablet (reference) formulations. Overall, bioavailability appeared to be higher for the capsule compared with the tablet formulation based on test-to-reference pharmacokinetic variable ratios for the parent compound alone. However, additional analyses based on the sulfide and sulfone metabolites of sulindac with the same pharmacokinetic variables indicated similar chemopreventive exposures between the capsule and tablet formulations. These data support the use of sulindac capsules, which can be readily prepared with matching placebos, in future blinded chemoprevention trials. (Cancer Epidemiol Biomarkers Prev 2008;17(3):674–9)